Prominent Germany Research Centers Partner with Boehringer Ingelheim to Test Monoclonal Antibody Targeting SARS-CoV-2

Prominent Germany Research Centers Partner with Boehringer Ingelheim to Test Monoclonal Antibody Targeting SARS-CoV-2

Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of BI 767551, a new SARS-CoV-2 neutralizing antibody. By combining UKK, UMR and DZIF’s expertise in virology, immunology and clinical investigation with Boehringer Ingelheim’s expertise in developing and manufacturing therapeutic antibodies, the partners developed BI 767551 as a potential new therapeutic and preventive/prophylactic option for fighting COVID-19.  This effort would be similar to the monoclonal antibody initiatives in the U.S. involving Regeneron, Eli Lilly, AstraZeneca and GlaxoSmithKline and Vir Biotechnology.

Important Research Targeting COVID-19

Virus neutralizing antibodies are expected to become an important line of defense against SARS-CoV-2, complementing vaccines and nonpharmaceutical interventions. They are being investigated as a therapy option for individuals with mild or severe infections, but also as prevention or prophylaxis in non-infected people with a high risk of infection or at risk of serious outcomes. Directly delivering BI 767551 to the lung by inhalation has the potential to provide fast acting protection from virus infection in the respiratory tract.

The Investigational Product

The new antibody BI 767551 was derived from blood samples of recovered COVID-19 patients at UKK, examined for SARS-CoV-2 neutralization at UMR and developed further in collaboration with Boehringer Ingelheim. The clinical study will be led by Prof. Florian Klein and Prof. Gerd Fätkenheuer at UKK and Boehringer Ingelheim will supply the antibody.  “With BI 767551, we aim to provide an effective option for preventing and treating COVID-19,” explains Prof. Florian Klein, Director of the Institute for Virology at the Cologne University Hospital and Principal Investigator at the DZIF.

”Monoclonal antibodies are a promising component in the fight against new viruses, such as the SARS-CoV-2. If this antibody turns out to be effective against COVID-19, this finding could be helpful in the current and also in future epidemics and pandemics. I am glad that we are able to assist in the development of this compound,” says Prof. Stephan Becker, Director of the Institute of Virology at University of Marburg and Coordinator Emerging Infections, DZIF.

“We are excited to contribute to the development of BI 767551 in collaboration with our partners, with the aim to provide an innovative SARS-CoV-2 neutralizing antibody, combining a systemic with an inhaled route of administration” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit.

The Studies

The Phase 1/2a studies (NCT04631705NCT04631666) will evaluate the safety, pharmacokinetics and antiviral activity of the antibody. In Phase 1, the antibody will be administered to participants either with a single infusion or a single inhalation. If the antibody is well tolerated, late-stage confirmatory studies will be conducted.

Research Center Participants

The University Hospital of Cologne is a maximum care hospital with more than 1.570 beds. It is recognized as an important research center as well as for its high-class medical education and outstanding medical care and treatment to its patients. More than 375,000 patients incl. more than 63,000 inpatients are treated per year. With nearly 11.000 employees the University Hospital of Cologne is one of largest employers in Cologne and one of Germanys largest medical centers.

The University of Marburg is the university with the longest tradition in Hesse. Founded in 1527, it offers excellent teaching in a wide range of subjects in a total of 16 departments to its approximately 24.000 students. Trendsetting topics with high relevance for society determine research in Marburg include research on highly pathogenic viruses. Further information: www.uni-marburg.de/en

Over 500 doctors and scientists from 35 establishments collaborate at the German Center for Infection Research (DZIF), jointly developing new approaches to prevent, diagnose and treat infectious diseases. The scientists at the DZIF pursue the aim of strategically transferring the results from basic research into clinical application. This process is called translation. Further information can be found at https://www.dzif.de/en

About Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what this company strives to accomplish, the largest privately held pharmaceutical company in the world. Their mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. Consequently, they position that they possess more freedom to pursue their long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where the German firm can do the most good. As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for their three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. The company’s significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life. They realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, the company seeks to accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come. More information about Boehringer Ingelheim can be found here or in their annual report here.

Call to Action: TrialSite monitors all of the major COVID-19 monoclonal antibody clinical development efforts. For updates sign up for the daily newsletter.